Yong Sik Jung

Yong Sik Jung

Auto-generated profile, based on publicly available information

Yong Sik Jung

Department of Surgery, Ajou University School of Medicine, Suwon, South Korea

Research Focus & Metrics

Academic Career Length

57Years (1970-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
WKWoojae Kim
Woojae Kim
KKKu Sang Kim
Ku Sang Kim
JLJeong Eon Lee
Jeong Eon Lee
DNDong-Young Noh
Dong-Young Noh
SKSung-Won Kim
Sung-Won Kim
Rae Woong ParkRae Woong Park
Rae Woong Park
Kim W, et al. J Breast Cancer. 2012 Jun;15(2):230-238. http://dx.doi.org/10.4048/jbc.2012.15.2.230

1 January 2012 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
HSHee Ri Na Seo
Hee Ri Na Seo
KNKuk Young Na
Kuk Young Na
HYHyun Ee Yim
Hyun Ee Yim
TKTae Hee Kim
Tae Hee Kim
DKDoo Kyoung Kang
Doo Kyoung Kang
KKKu Sang Kim
Ku Sang Kim
Seo HR, et al. J Breast Cancer. 2012 Mar;15(1):111-118. http://dx.doi.org/10.4048/jbc.2012.15.1.111

10 February 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HKHyun-Ah Kim
Hyun-Ah Kim
JLJong Won Lee
Jong Won Lee
SNSeok Jin Nam
Seok Jin Nam
BPByeong-Woo Park
Byeong-Woo Park
SISeock-Ah Im
Seock-Ah Im
OGon behalf of the Korean Breast Cancer Study Group
on behalf of the Korean Breast Cancer Study Group
PURPOSE: The addition of ovarian function suppression (OFS) for 5 years to tamoxifen (TAM) for treatment of premenopausal patients with breast cancer after completion of chemotherapy has beneficial effects on disease-free survival (DFS). This study evaluated the efficacy of adding 2 years of OFS to TAM in patients with hormone receptor–positive breast cancer who remain in a premenopausal state or resume ovarian function after chemotherapy. PATIENTS AND METHODS: We enrolled 1,483 premenopausal women (age ≤ 45 years) with estrogen receptor–positive breast cancer treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy. Ovarian function was assessed every 6 months for 2 years since enrollment on the basis of follicular-stimulating hormone levels and vaginal bleeding history. If ovarian function was confirmed to be premenopausal at each visit, the patient was randomly assigned to complete 5 years of TAM alone (TAM-only) group or 5 years of TAM with OFS for 2 years that involved monthly goserelin administration (TAM + OFS) group. DFS was defined from the time of enrollment to the time of the first event. RESULTS: A total of 1,293 patients were randomly assigned, and 1,282 patients were eligible for analysis. The estimated 5-year DFS rate was 91.1% in the TAM + OFS group and 87.5% in the TAM-only group (hazard ratio, 0.69; 95% CI, 0.48 to 0.97; P = .033). The estimated 5-year overall survival rate was 99.4% in the TAM + OFS group and 97.8% in the TAM-only group (hazard ratio, 0.31; 95% CI, 0.10 to 0.94; P = .029). CONCLUSION: The addition of 2 years of OFS to TAM significantly improved DFS compared with TAM alone in patients who remained premenopausal or resumed ovarian function after chemotherapy.

1 August 2015 in British Journal of Radiology
Verified
Journal Article
Open access
SYSeulgi You
Seulgi You
DKD K Kang
D K Kang
YJY S Jung
Y S Jung
YAY-S An
Y-S An
GJG S Jeon
G S Jeon
TKT H Kim
T H Kim
To evaluate the diagnostic performance of ultrasound, MRI and fluorine-18 fludeoxyglucose positron emission tomography (¹⁸F-FDG PET)/CT for the diagnosis of metastatic axillary lymph node (ALN) after neoadjuvant chemotherapy (NAC) and to find out histopathological factors affecting the diagnostic performance of these imaging modalities. From January 2012 to November 2014, 191 consecutive patients with breast cancer who underwent NAC before surgery were retrospectively reviewed. We included 139 patients with ALN metastasis that was confirmed on fine needle aspiration or core needle biopsy at initial diagnosis. After NAC, 39 (28%) patients showed negative conversion of ALN on surgical specimens of sentinel lymph node (LN) or ALN. The sensitivity of ultrasound, MRI and PET/CT was 50% (48/96), 72% (70/97) and 22% (16/73), respectively. The specificity of ultrasound, MRI and PET/CT was 77% (30/39), 54% (21/39) and 85% (22/26), respectively. The Az value of combination of ultrasound and PET/CT was the highest (0.634) followed by ultrasound (0.626) and combination of ultrasound, MRI and PET/CT (0.617). The size of tumour deposit in LN and oestrogen receptor was significantly associated with the diagnostic performance of ultrasound (p < 0.001 and p = 0.009, respectively) and MRI (p = 0.045 and p = 0.036, respectively). The percentage diameter decrease, size of tumour deposit in LN, progesterone receptor, HER2 and histological grade were significantly associated with the diagnostic performance of PET/CT (p = 0.023, p = 0.002, p = 0.036, p = 0.044 and p = 0.008, respectively). On multivariate logistic regression analysis, size of tumour deposit within LN was identified as being independently associated with diagnostic performance of ultrasound [odds ratio, 13.07; 95% confidence interval (CI), 2.95-57.96] and PET/CT (odds ratio, 6.47; 95% CI, 1.407-29.737). Combination of three imaging modalities showed the highest sensitivity, and PET/CT showed the highest specificity for the evaluation of ALN metastasis after NAC. Ultrasound alone or combination of ultrasound and PET/CT showed the highest positive-predictive value. The size of tumour deposit within ALN was significantly associated with diagnostic performance of ultrasound and PET/CT. This study is about the diagnostic performance of ultrasound, MRI, PET/CT and combination of each imaging modality for the evaluation of metastatic ALN after NAC. Of many histopathological factors, only the size of tumour deposit within ALN was an independent factor associated with the diagnostic performance of ultrasound and PET/CT.

1 September 2011 in Clinical Oncology
Verified
Journal Article
Closed access
SHSang Ah Han
Sang Ah Han
SPSue K. Park
Sue K. Park
SASei Hyun Ahn
Sei Hyun Ahn
MLMin Hyuk Lee
Min Hyuk Lee
DNDong-Young Noh
Dong-Young Noh
KGKorean Breast Cancer Study Group
Korean Breast Cancer Study Group

1 January 2012 in Journal of Computer Assisted Tomography
Verified
Journal Article
Closed access
TKTae Hee Kim
Tae Hee Kim
DKDoo Kyoung Kang
Doo Kyoung Kang
HYHyunee Yim
Hyunee Yim
YJYong Sik Jung
Yong Sik Jung
KKKu Sang Kim
Ku Sang Kim
SKSeok Yun Kang
Seok Yun Kang
Purpose The objectives of the study were to analyze the tumor shrinkage pattern on magnetic resonance imaging (MRI) after neoadjuvant chemotherapy and to evaluate whether there is any difference in shrinkage pattern between pathological responder and nonresponder groups. In addition, we wanted to compare tumor diameter obtained from MRI with histological diameter according to the tumor shrinkage pattern. Methods Between July 2008 and December 2010, 55 consecutive patients (56 lesions) with pathologically proven breast cancer who underwent neoadjuvant chemotherapy followed by surgery were retrospectively enrolled. The shrinkage pattern was classified into 4 categories: I (concentric shrinkage without surrounding lesion), II (concentric shrinkage with surrounding lesions), III (shrinkage with residual multinodular lesions, and IV (diffuse contrast enhancement in whole quadrants). Histological regression was scored on a 5-point scale regarding tumor cellularity reduction (Miller-Payne grading system). Patients with Miller-Payne grade 1 or 2 were classified into the nonresponder group, and patients with grade 3, 4, or 5 were in the responder group. Results Of 56 lesions, pattern I was seen in 29 lesions, pattern II in 13 lesions, pattern III in 5 lesions, and pattern IV in 4 lesions. Three lesions were not visualized on MRI after neoadjuvant chemotherapy, and 2 lesions were increased in size. There was a statistically significant difference in the tumor shrinkage pattern between responder and nonresponder groups (P = 0.017). All 5 lesions with type III shrinkage pattern were found in the responder group, and all 4 lesions with pattern IV were in the nonresponder group. Magnetic resonance imaging diameter of lesions with types I, II, and IV patterns showed significant correlation with the histological diameter. Among them, the correlation factor was highest in pattern IV (ρ = 0.94, P < 0.001) followed by pattern I (ρ = 0.67, P < 0.01) and pattern II (ρ = 0.502, P = 0.08). However, in type III shrinkage pattern, tumor size measured on MRI was not significantly correlated with histological size (P = 0.87). Conclusions Types III and I shrinkage patterns were more frequently observed in the pathological responder group, and type IV was more frequently noted in the nonresponder group. Tumor diameter measured on MRI showed strong correlation with histological diameter in lesions with types I and IV shrinkage patterns, whereas lesions with type III did not show significant correlation. Type II pattern showed similar frequencies between the 2 groups and moderate correlation between sizes obtained from MRI and histology.